Scopus BioPharma Inc.
DelistedCIK 1772028fmd_122S2NBS8E6NXTVCM7E3G49DW2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Jun 30, 2023, 16 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 |
| Research and development | 0 | 7 | 15 | 3 |
| Total operating expenses | 3 | 10 | 28 | 12 |
| Operating income | (3) | (10) | (28) | (12) |
| Interest expense | 0 | 1 | 1 | 0 |
| Other non-operating income (expense) | – | (1) | 1 | – |
| Net income | (3) | (11) | (27) | (12) |